SNNC (Sibannac) EV-to-EBIT: -9.66 (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sibannac EV-to-EBIT?

Sibannac SNNC -3.53% EV-to-EBIT is -9.66 as of Aug. 11, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sibannac's Enterprise Value is $1.11 Mil. Sibannac's EBIT for the trailing twelve months (TTM) ended in Feb. 2017 was $-0.12 Mil. Therefore, Sibannac's EV-to-EBIT for today is -9.66.

The historical rank and industry rank for Sibannac's EV-to-EBIT or its related term are showing as below:

SNNC' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.66   Med: 0   Max: 0
Current: -9.66

SNNC's EV-to-EBIT is not ranked
in the Drug Manufacturers industry.
Industry Median: 15.66 vs SNNC: -9.66

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sibannac's Enterprise Value for the quarter that ended in Feb. 2017 was $4.18 Mil. Sibannac's EBIT for the trailing twelve months (TTM) ended in Feb. 2017 was $-0.12 Mil. Sibannac's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2017 was -2.75%.


Sibannac  (OTCPK:SNNC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sibannac's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2017 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2017 ) =EBIT / Enterprise Value (Q: Feb. 2017 )
=-0.115/4.18294
=-2.75 %

Sibannac's Enterprise Value for the quarter that ended in Feb. 2017 was $4.18 Mil.
Sibannac's EBIT for the trailing twelve months (TTM) ended in Feb. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sibannac EV-to-EBIT Related Terms


Sibannac EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Sibannac's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sibannac EV-to-EBIT Chart

Sibannac Annual Data
Trend Aug11 Aug12 Aug13 Aug14 Aug15 Aug16
EV-to-EBIT
Get a 7-Day Free Trial 0.00 0.00 -537.13 -2.57 -13.11

Sibannac Quarterly Data
May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.15 0.00 0.00 0.00

SNNC vs LIVC, OTTV, FPTA: EV-to-EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sibannac's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sibannac EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sibannac's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sibannac's EV-to-EBIT falls into.



Sibannac EV-to-EBIT Calculation

Sibannac's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.111/-0.115
=-9.66

Sibannac's current Enterprise Value is $1.11 Mil.
Sibannac's EBIT for the trailing twelve months (TTM) ended in Feb. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -9.66 mean?
Sibannac (SNNC) has a EV-to-EBIT of -9.66 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sibannac and its competitors.
Is Sibannac's EV-to-EBIT too high?
Sibannac's current EV-to-EBIT is -9.66.
How does Sibannac's EV-to-EBIT compare to LIVC and OTTV?
Sibannac's EV-to-EBIT of -9.66 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sibannac and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sibannac's current EV-to-EBIT is -9.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sibannac stock overvalued right now?
Sibannac (SNNC) has a current EV-to-EBIT of -9.66. The current EV-to-EBIT is -9.66. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sibannac (SNNC), the current EV-to-EBIT is -9.66 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sibannac Business Description

Address 8657 N Caballo Circle, Paradise Valley, AZ, USA, 85253
Sibannac Inc is a cannabis research and development company with a portfolio of hemp beauty and body products, hemp animal care products, hemp clothing and accessories, and hemp paper and plastic products. Its products include oils, creams, lotions, treats, foods, shirts, pants, and dresses, and it also develops new hemp products. The group manufactures its products in Geneva, New York, and Charlotte, North Carolina. Its subsidiary business units include NOHO, Cherryology, and RaD8 Life, and associated brands include NOHO, Higher Times, Starwalker Cafe, The Meru Sky, consumer brands such as Converse, Titleist, FootJoy, Coca-Cola, Pepperidge Farm, and practitioner and nutraceutical brands including ChiroTouch, Emerson Ecologics, Reserveage, Gaia Herbs, Organic India, and NeoCell.